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What is known 
Steroids and Immunosuppressants are the universal treatment of Idiopathic Nephrotic 
Syndrome 
What is new 






The aim of the surveys conducted by the Idiopathic Nephrotic Syndrome Working Group 
(WG) of the ESPN was to study the possible variability of treatment in Europe at different 
stages of the disease by means of questionnaires sent to members of the working group. Four 
surveys have been completed: the treatment of the first flare, the treatment of the first relapse 
and the issue of steroid dependency, the use of rituximab, the management of steroid resistant 
patients. A uniform treatment of the first flare was applied in only 3 countries and 10 
additional centers have adopted one of the 3 main protocols. Reported treatment of the first 
relapse was relatively uniform whereas the use of additional immunosuppressant in steroid 
dependency was widely variable. Rituximab had already been used in hundreds of patients 
although the formal evidence of efficiency in steroid dependency was relatively recent at the 
time of the survey. The definition of steroid resistance was variable in the European centers 
but strikingly, the first line treatment was uniform throughout the centers and included the 
combination of prednisone plus calcineurin antagonists. 
Conclusion. The variability in the approach of Idiopathic Nephrotic Syndrome is 
unexpectedly large and affects the treatment of the first flare, the strategies in case of steroid 
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Idiopathic nephrotic syndrome (INS) is not a frequent disease but not an orphan disease. The 
annual incidence in the population below 16 years of age is between 1.2 to 3.4 new cases per 
100,000 [6]. It means that 1000 to 1500 new cases are occurring yearly in the European 
Union. Roughly half of them will be steroid dependent and will have a median course of 10 
years, meaning that 6000 to 16,000 pediatric patients (equivalent to 6 to 18 per 100.000 of 
general population <16 years of age) are currently treated with steroids or immunosuppressive 
drugs. One of the main difficulties in gathering multicentre data for clinical studies on INS is 
due to the adoption of different treatment protocols as well as the definition of outcomes and 
resistance to treatment. This issue is particularly important in INS where elements of the 
diagnosis and the prognosis are based on the response to the very initial phase of the 
treatment.  
The aim of the surveys conducted by the Idiopathic Nephrotic Syndrome Working Group 
(WG) of the ESPN was to study the possible variability of treatment in Europe at different 
stages of the disease by means of questionnaires sent to members of the WG. These 
questionnaires aimed at exploring different debated issues of INS treatment. The global 
conclusions are that the variability is unexpectedly large and not always understandable, even 
when a general consensus had apparently been reached.   
 
Methods 
Four surveys have been completed from 2013 to 2015 and sent to the 52 members of the INS 
working group.  
Survey 1 (first flare). The treatment of the first flare was investigated using a template where 
the classical protocols were recalled along with a space for the single center’s individual 
approach. Each participant was asked to fill the available cells of the column space entitled 
“your protocol” with the local protocol of treatment of the first flare. 
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Survey 2 (First relapse and steroid dependency). The treatment of the first relapse and the 
management of steroid dependent patients were investigated using a clinical case. The first 
query aimed at describe the treatment of the first relapse in each center. According to the 
answer, a second query was on the timing and choice of additional immunosuppressive 
treatment in each center. 
Survey 3 (Rituximab). The use of rituximab was investigated using two successive 
questionnaires. The first questionnaire mainly aimed at define the criteria to treat with 
Rituximab (steroid dependency, duration or severe complication of the disease) and the 
second questionnaire was dedicated to the technical points: dose, number of infusions for the 
initial cure, duration of B cell depletion, antimicrobial prophylaxis, withdrawal of 
conventional immunosuppressive drugs and steroids. 
Survey 4 (Steroid resistant forms). The management of steroid resistant patients was 
investigated using a template to fill in. The template contained open criteria of the definition, 
the use of renal biopsy and the access to genetic testing first line treatment, duration of the 
treatment prior to consider failure, criteria of success.  
 
Results 
The surveys were sent to 52 centers and answered by 40 centers from 19 countries. There 
were 29, 16, 27 and 18 answers for Survey 1, 2, 3 and 4 respectively (Table I). 
First flare (Table II). The questionnaire was returned by 26 individual centers. In addition,  3 
countries, Denmark, Germany and France that applied a uniform nationwide treatment were 
considered as one answer while they represent dozens of individual centers. Surprisingly, 
those 3 protocols were relatively similar but differed by the cumulative dose of prednisone 
(3360 mg/m² for Denmark and Germany and 3390 mg/m² for France), the use of intravenous 
methylprednisolone in case of oral steroid resistance (Germany and France), and the tapering 
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sequence (only in France). In other centers, the variability of the cumulative dose ranged from 
2240 mg/m² to 4245 mg/m². Consistently the duration of treatment also varied from 8 to 24 
weeks. Other important results showed that 1) all centers gave 60 mg/m²/day of prednisone (n 
= 14) or prednisolone (n = 15) to start the treatment; 2) all centers were limiting the daily dose 
during the first weeks of treatment, 18 of them to less than 60 mg/day meaning that patients 
over 1 m² (about 30 Kg body weight) were receiving less than the nominal cumulative dose 
mentioned in Table I; 3) 20/29 protocols included a sequence of several steps of steroid 
tapering before withdrawal; 4) 20/29 were using an intravenous (IV) methylprednisolone test 
in case of steroid resistance at the end of the period of full oral daily dose. Another 
unexpected fact was the variability of the protocols within large countries (Italy, Russia, Spain 
and Turkey) as well as within smaller countries (Belgium, Croatia and Serbia).  Finally, half 
of the centers (13/26) were following one of the 3 main protocols emerging from the literature 
(Table IV): 2 centers (#01 to #02, Table I) had a protocol close to the model of the 
International Study of Kidney Diseases in Children (ISKDC, Table IV), 7 centers (#13 to #19, 
Table I) had a protocol close to the model of the German Society for Pediatric Nephrology 
(GPN, Table IV) and 4 (#24 to #27, Table I) had a protocol close to that of the French Société 
de Néphrologie Pédiatrique (SNP, Table IV).  
First relapse and steroid dependency. The survey adopted the form of a clinical quiz that was 
compiled by 16 centers. The clinical case presented a typical steroid dependent patient 
relapsing 5 days after the withdrawal of prednisone. Reported treatment of the first relapse 
was relatively uniform and consisted of a short period of daily prednisone limited to the time 
to obtain a remission in 1 center, plus 3 days in 9/16 centers and plus 5-7 days in 5 centers. 
Only one center reported treating the 1st relapse similarly to a first flare in the absence of 
significant steroid toxicity. A single treatment with prednisone lasting from 1 to 6 months 
without any prevention of further relapses was the choice of 7 centers. A systematic 
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prevention of further relapses was undertaken as soon as the first early relapse by 8 centers: 5 
gave long lasting alternate day prednisone therapy, 1 levamisole, 1 cyclosporine and 1 an 
unconventional combination of levamisole, mycophenolate and subcutaneous polyclonal 
immunoglobulins. In the last center, a treatment with mycophenolate was given only in case 
of significant signs of steroid toxicity. Three centers also mentioned that cyclophosphamide or 
rituximab could be an option as soon as the first relapse in case of relapse prior to the 
withdrawal of steroids. 
At the second relapse, immunosuppressant drugs were systematically given to patients in 9 
centers. Mycophenolate was the first option in the majority of those centers and only 2 
considered cyclophosphamide or rituximab at this stage. Four centers did not consider any 
systematic prevention of further relapses at this stage of the disease but mycophenolate or 
levamisole were conditioned to steroid toxicity in 3/4 centers and cyclophosphamide in 1/4.  
The 3 last centers reported no answer for the second relapse and beyond.  
Rituximab. The questionnaire was sent in 2 parts. Twenty-seven centers answered the first 
part and 13 the second part. One center had no experience at all. By contrast, several hundreds 
of patients have been treated with rituximab in the 26 other centers. Three centers reported 
more than 50 patients each and 4 other centers reported 20 to 50 patients each. The last 18 
centers had a more marginal experience with less than 10 patients. The major indication of 
treatment was steroid dependency. Other frequent indications included steroid resistance (8 
centers) and long lasting treatment with immunosuppressant (8 centers). A minimum of at 
least a 3 year-duration of nephrotic syndrome was reported by 7 centers but 2 centers had 
clearly no lower limit for prescription. Rituximab was the last line of treatment for 3 centers. 
Either non-compliance or complications were an indication in 6 centers. Strikingly, costs of 
rituximab were not covered by healthcare insurance in Belgium and Poland in 2015. 
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Of the 13 centers that answered the 2nd part of the questionnaire, 12 were initiating the 
treatment by 1 (8 centers) or 2 infusions at 1 week of distance (4 centers) while only 1 center 
followed the classic protocol consisting of 4 infusions in 4 weeks. The dose of one infusion 
was 375 mg/m² for all centers except 1 that reported a unitary dose of 750 mg/m². Reinfusion 
was performed if B cell repletion was observed within 6 months after the first infusion in 6 
centers and only in case of relapse in 4 centers. A systematic long-lasting B cell depletion of 
12 and 18 months was achieved in 2 centers. An alternate protocol adopted by 1 center was to 
treat any relapses with rituximab in steroid dependent patients, allowing to rapidly stop the 
oral treatment. A reinfusion was never done in one center. A withdrawal of all oral drugs was 
attempted by all centers with a delay varying from 1 month (in 3 centers) to 12 months. 
Steroid resistant forms. Eighteen centers answered the survey. The heterogeneity of the 
definition of steroid resistance is shown in Table III. The first line treatment that was adopted 
by the 18 centers was the association of calcineurin inhibitors, either cyclosporine (15 centers) 
or tacrolimus (3 centers). The patient was considered multidrug resistant in case of no 
response to the association of calcineurin inhibitor and prednisone for a period of 3 months (2 
centers), 6 months (8 centers) or 9 months (5 centers) (3 centers did not answer the question). 
Partial response to treatment was considered 50% proteinuria reduction by most centers and 
combined to serum albumin increase in 3 centers. In case of partial response, mycophenolate 
was added as a second line treatment in 13 centers. Only isolated centers propose as third line 
treatment with apheretic techniques, intravenous high doses immunoglobulin and rituximab. 
One center had no additional treatment in case of multidrug resistance. All centers decided to 
withdraw immunosuppressive therapies, shifting to exclusive supportive cares basing on 




Idiopathic Nephrotic Syndrome affects children all over the globe and one should expect that 
they should be treated with common and shared protocols. Here, we report the results of 
surveys that concern the treatment of children with INS in the European area. The data are 
coming from a sample of the European centers of Pediatric Nephrology belonging to the INS 
working group of the ESPN and that answered to the 4 surveys. Despite a relatively low 
number of participating centers compared to the total number of centers in Europe that is 
clearly a limitation of the study, the surveys show large variations of treatment strategies at all 
steps of the management of idiopathic nephrotic syndrome in the European area as already 
reported elsewhere in the world [16,21].  
Numerous guidelines, meta-analyses [9] and follow-up series on the treatment of the first flare 
of nephrotic syndrome have been released in the literature by Pediatric Nephrology societies, 
consortium of centers or single centers [8,12,18,25]. At least 7 randomized prospective trials 
have tested different protocols of steroid therapy [8]. The fact is that the literature shows 
substantial differences of treatment of the first flare according to countries and centers. In 
addition to the protocol described in the literature as the International Study of Kidney 
Disease in Childhood [3], the GPN (formerly named Arbeitgemeinshaft für Pädiatrische 
Nephrologie – APN) protocol [5] and the protocol of the Société de Néphrologie Pédiatrique 
[2], US and India guidelines recommend a protocol that is very similar to those of the GPN 
[1,8]. The protocol recommended by the KDIGO is less well defined in term of duration of 
treatment and composes with different sources [14]. The main details of protocols that are 
used in Europe are shown in Table IV. They are quite different in terms of duration and 
cumulated dose of steroid therapy, the tapering protocol and the option of intravenous 
methylprednisolone in case of oral steroid resistance. As a matter of fact, out of the European 
centers of Pediatric Nephrology, one half of the centers reported to use the ISKDC or the 
APN or the SNP protocols while the other half of centers have a local protocol that is more or 
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less a mix of the 3 main protocols. The variability in dose and duration of prednisone (or 
prednisolone) has already been reported in Italy, not only in General Pediatrics Units but also 
in those specialized in Pediatric Nephrology [20]. Noteworthy, 2 centers using the classical 
ISKDC protocol and 3 using the APN protocol have reported the use of IV 
methylprednisolone in case of oral steroid resistance while this option is not classically 
included in those protocols.. The most surprising finding is that, according to this survey, a 
total of 13 European centers are treating patients below the KDIGO recommendations of 
minimum steroid therapy: less than 12 weeks of duration or less than 3360 mg/m² of 
cumulative dose corresponding to the sum of 4 weeks at 60 mg/m²/day and 6 weeks at 40 
mg/m² e.o.d. [14]. Nevertheless, 2 recent prospective randomized trials have shown that a 
cumulative dose of 2240 mg/m² of prednisone had the same effect on the outcome as 3500 
and 3900 mg/m² [24,26]. By contrast, a less recent prospective trial from Japan also showed 
that patients under 4 years of age had a strong benefit of a high cumulative dose of 
prednisolone [11]. At the other end, none of the centers participating to this survey reported  
steroid overtreatment contrasting with a recent Italian report where patients in 2 pediatric 
nephrology units are treated with cumulative dose of prednisone over 5000 mg/m² [20]. 
However, our data clearly highlights the need to discuss common and shared European 
guidelines aimed at optimizing steroid therapy according to one protocol with different 
options. Based on the data of the literature and on the experience of centers, European 
guidelines should at least state about uniform dose of steroids and define one option for the 
tapering protocol and the test with IV methylprednisolone. 
In contrast with the treatment of the first flare, the steroid therapy of the first relapse which 
has never been the objective of a randomized prospective trial is very homogenous in Europe. 
All but one centers treat the first relapse with a shortened duration of daily prednisone and a 
rapid tapering of the dose from 0 to 7 days after the remission of proteinuria, consistent with 
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the KDIGO recommendations [14]. At this point, differences between centers concern the 
duration of steroid therapy and the use of an additional second-line treatment. A prevention of 
relapses by either long lasting steroid therapy or levamisole was reported by seven centers as 
soon as the first relapse. Beyond the first relapse, KDIGO recommendations are vague, 
particularly on the chronology of each possible steroid sparing treatment. No difference are 
suggested between the treatments that prevent relapses as long as they are continued but have 
no remnant effect after withdrawal (levamisole, mycophenolate and calcineurin inhibitors) 
and those that clearly show the ability to disrupt the course of the disease in long term follow-
up series (cyclophosphamide, rituximab) [14]. At the second relapse, nine European centers 
considered an additional treatment and four reported using an additional treatment only in 
case of steroid toxicity. Among the nine centers that reported an additional treatment, only 
two reported the early use of cyclophosphamide or rituximab. The duration of the disease was 
never explicitly mentioned as an indication of additional treatment. 
Rituximab has now been fully recognized as an efficient treatment of steroid dependent 
patients with a high rate of evidence since the end of 2014 and the release of the first 
randomized controlled trial [13]. Nevertheless, the efficiency of rituximab has been 
empirically recognized by clinicians for several years [4] while more than 300 patients have 
been reported in the survey at the end of 2014. Variations in the use of rituximab are 
somehow limited: most of the centers reported the same unitary dose of 375 mg/m² and the 
number of initial infusion was 1 or 2. Long-lasting B cell depletion [22] has been used by 2 
centers but one should recall that the risk of life-threatening infections might be proportional 
to the duration of B cell depletion [23]. An alternative way might be to systematically treat 
relapses in steroid dependent patients with one infusion of rituximab in order to stop oral 
treatments rapidly and to delay the next relapse. Nevertheless, the best way to use rituximab 
remains to be defined in the near future. 
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Steroid resistance is a condition of high morbidity leading to end stage renal failure or to 
long-lasting and heavy immunosuppressive drug therapy [17,27]. The definition of steroid 
resistance is very heterogeneous in the survey. Whereas the prevalence of steroid sensitivity is 
proportional to the duration and the cumulative dose of steroids [19], the resistance after 4 
weeks of oral prednisone might have a different significance in term of difficulty to treat than 
the resistance after 8 weeks of oral prednisone plus 3 intravenous methylprednisolone pulses. 
Nevertheless, the first-line treatment is similar in all centers regardless to the definition. All 
centers reported using a first-line of prednisone and calcineurin antagonists, consistently with 
the KDIGO recommendations [15]. Mycophenolate is a common drug included in the 
maintenance treatment, specially in partial response. Positive genetic testing is a major cause 
of immunosuppressive treatment withdrawal in all centers suggesting that the first line 
treatment is systematically started before genetic results likely to be delayed in most cases. 
The other criteria that leads to withdrawal of immunosuppressive therapy is the time to 
unresponsiveness that ranges between 3 and 9 months, defining the multidrug resistance. In 
this case, experimental therapeutical options using plasma exchange or immunoglobulin 
removal are a choice for only 2 centers. 
To conclude, a lot of work remains to be done in order to homogenize the treatment of 
idiopathic nephrotic syndrome based on high-quality evidence. The choice of treatment 
remains largely dependant on each physician’s clinical experience at all steps. This variability 
of therapeutic approaches deserves some attention and supports the commitment of the INS 
Working Group of the ESPN to build guidelines and consensus.  
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